- Contract Awards
Emergent BioSolutions (NYSE: EBS) will further develop a licensed drug against Ebola under a potential 10-year, $704 million contract from the Department of Health and Human Services. Development services on Ebanga under the contract are valued at $121 million and the award includes a five-year option worth $583 million for the U.S. government to pr...











